Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation
- PMID: 35444301
- DOI: 10.1038/s41569-022-00714-9
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation
Comment on
-
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3. Lancet. 2022. PMID: 35385695 Clinical Trial.
References
Original article
-
- Piccini, J. P. et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet https://doi.org/10.1016/S0140-6736(22)00456-1 (2022) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
